A Milestone-Based Framework for Characterizing Time-Varying Treatment Effects in Immunotherapy Trials

2026-04-27

AI Summary

Immune checkpoint inhibitors often induce time-varying, heterogeneous survival effects that cannot be adequately captured by conventional hazard ratios. To address this limitation, this study proposes a milestone-based analytical framework that disentangles early outcomes from long-term survival by integrating milestone survival probabilities with the tau statistic. This approach effectively characterizes dynamic treatment patterns under non-proportional hazards, where short-term risks and late-onset benefits coexist. Applied to three phase III clinical trials, the method successfully uncovers time-dependent therapeutic effects overlooked by traditional analyses, precisely identifying the onset of clinical benefit and distinguishing between short- and long-term efficacy profiles. The proposed framework thus offers a novel paradigm for the accurate evaluation of immunotherapies.

Technology Category

• Machine Learning: Calibration & Uncertainty Quantification
• Reasoning under Uncertainty: Sequential Decision Making
• Search and Optimization: Mixed Discrete/Continuous Search

Application Category

• User Modeling, Personalization and Recommendation: Metrics for user behavior and evaluating success
• Security and Privacy: Large-scale security measurements
• Search and Retrieval-Augmented AI: Web learning to rank, online learning, and counterfactual learning for ranking

Abstract

Immune checkpoint inhibitor--based therapies often produce heterogeneous survival responses, including early risk, delayed treatment benefit, and durable long-term survival in a subset of patients. In these settings, conventional summary measures such as the hazard ratio may not adequately describe how treatment effects evolve over follow-up. We propose a milestone-based framework that separates long-term survival beyond a clinically meaningful time point from earlier outcomes and provides a practical way to characterize patient heterogeneity in treatment response. The framework summarizes treatment differences through milestone survival probabilities and, among patients who do not reach the milestone, characterizes short-term treatment ordering over time using a tau-based summary that helps identify hazard reversal. We illustrate the approach using reconstructed individual-level data from three landmark phase III trials: CheckMate~067, CheckMate~227, and CLEAR. Across these examples, the framework captures patterns that are difficult to summarize with conventional measures, including settings in which early disadvantage coexists with later durable benefit. It also helps clarify when treatment benefit begins to emerge and how short-term and long-term effects differ within the same trial. This approach provides a clinically interpretable and statistically principled way to evaluate heterogeneous and time-varying treatment effects in oncology trials with nonproportional hazards.

Problem

• time-varying treatment effects
• heterogeneous survival responses
• nonproportional hazards
• immunotherapy trials
• milestone survival

Innovation

• milestone-based framework
• time-varying treatment effects
• immune checkpoint inhibitors
• nonproportional hazards
• treatment heterogeneity